Atom Investors LP Has $762,000 Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Atom Investors LP decreased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 62.0% in the 3rd quarter, Holdings Channel reports. The firm owned 45,265 shares of the company’s stock after selling 73,860 shares during the quarter. Atom Investors LP’s holdings in Cellebrite DI were worth $762,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. FMR LLC raised its stake in Cellebrite DI by 136.3% during the third quarter. FMR LLC now owns 5,616,757 shares of the company’s stock worth $94,586,000 after buying an additional 3,239,307 shares during the last quarter. Meitav Investment House Ltd. grew its holdings in Cellebrite DI by 29.7% during the 3rd quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company’s stock worth $34,797,000 after acquiring an additional 473,293 shares during the period. Pembroke Management LTD raised its position in shares of Cellebrite DI by 24.3% in the 3rd quarter. Pembroke Management LTD now owns 1,908,345 shares of the company’s stock worth $32,137,000 after acquiring an additional 372,619 shares in the last quarter. Principal Financial Group Inc. acquired a new position in shares of Cellebrite DI in the 3rd quarter valued at about $23,402,000. Finally, Renaissance Technologies LLC boosted its position in shares of Cellebrite DI by 22.1% during the 2nd quarter. Renaissance Technologies LLC now owns 1,183,700 shares of the company’s stock valued at $14,145,000 after purchasing an additional 214,600 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analysts Set New Price Targets

CLBT has been the subject of a number of research analyst reports. TD Cowen lifted their target price on Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Craig Hallum boosted their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC increased their target price on shares of Cellebrite DI from $17.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Lake Street Capital lifted their price target on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Cellebrite DI from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Cellebrite DI currently has an average rating of “Buy” and a consensus target price of $20.29.

Cellebrite DI Trading Up 0.2 %

Cellebrite DI stock opened at $20.40 on Wednesday. The firm has a market capitalization of $4.20 billion, a price-to-earnings ratio of -13.16, a price-to-earnings-growth ratio of 2.77 and a beta of 1.51. The firm’s fifty day moving average price is $18.35 and its two-hundred day moving average price is $15.31. Cellebrite DI Ltd. has a 1-year low of $7.91 and a 1-year high of $21.00.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. The business had revenue of $106.90 million for the quarter, compared to analysts’ expectations of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The firm’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.09 EPS. On average, research analysts forecast that Cellebrite DI Ltd. will post 0.32 EPS for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.